News
Beacon Therapeutics has completed the enrolment in its randomised, registrational Phase II/III VISTA trial of laru-zova.
BVI is a winner in the Research and Development, Investments, and Product Launches categories in the 2025 Medical Device ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback